Efficacy and tolerability of initial low-dose lenvatinib to treat differentiated thyroid cancer

Some patients with differentiated thyroid cancer (DTC) may require an initial low dose (LD) of lenvatinib. However, few studies have investigated the efficacy of LD lenvatinib. We compared the efficacy and tolerability of lenvatinib at an initial LD to those of the standard initial dose of 24 mg in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Haruhiko, Iwasaki, Hiroyuki, Takasaki, Hirotaka, Suganuma, Nobuyasu, Sakai, Rika, Masudo, Katsuhiko, Nakayama, Hirotaka, Rino, Yasushi, Masuda, Munetaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417556/
https://www.ncbi.nlm.nih.gov/pubmed/30855484
http://dx.doi.org/10.1097/MD.0000000000014774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417556/
https://www.ncbi.nlm.nih.gov/pubmed/30855484
http://dx.doi.org/10.1097/MD.0000000000014774

Ejemplares similares